Transforming growth factor-b 1 (TGF-β1), a multi-function polypeptide, is a double-edged sword in cancer. For some tumor cells, TGF-β1 is a potent growth inhibitor and apoptosis inducer. More commonly, TGF-β1 loses...Transforming growth factor-b 1 (TGF-β1), a multi-function polypeptide, is a double-edged sword in cancer. For some tumor cells, TGF-β1 is a potent growth inhibitor and apoptosis inducer. More commonly, TGF-β1 loses its growth-inhibitory and apoptosis-inducing effects, but stimulates the metastatic capacity of tumor cells. It is currently little known about TGF-β1-promoted cell migration in hepatocellular carcinoma (HCC) cells, let alone its mechanism. In this study, we found that TGF-β1 lost its tumor-suppressive effects, but significantly stimulated cell migration in SMMC-7721 human HCC cells. By FACS and Western blot analysis, we observed that TGF-β1 enhanced the expression of α5β1 integrin obviously, and subsequently stimulated cell adhesion onto fibronectin (Fn). Furthermore, we observed that TGF-β1 could also promote SMMC-7721 cells adhesion onto laminin (Ln). Our data also provided evidences that TGF-β1 induced epithelial-to-mesenchymal transformation (EMT) in SMMC-7721 cells. First, SMMC-7721 cells clearly switched to the spindle shape morphology after TGF-β1 treatment. Furthermore, TGF-β1 induced the down-regulation of E-cadherin and the nuclear translocation of β-catenin. These results indicated that TGF-β1-promoted cell adhesion and TGF-β1-induced epithelial-to-mesenchymal transformation might be both responsible for TGF-β1-enhanced cell migration.展开更多
目的观察髓芯减压值骨联合自体骨髓干细胞移植治疗早期股骨头坏死的临床疗效。方法根据国际骨循环研究学会（Association Research Circulation Osseous，ARCO）骨坏死分期标准，选取Ⅰ、Ⅱ期股骨头坏死32例（39髋），治疗组18例（24髋...目的观察髓芯减压值骨联合自体骨髓干细胞移植治疗早期股骨头坏死的临床疗效。方法根据国际骨循环研究学会（Association Research Circulation Osseous，ARCO）骨坏死分期标准，选取Ⅰ、Ⅱ期股骨头坏死32例（39髋），治疗组18例（24髋），对照组14例（15髋）治疗组经过自体骨髓干细胞采集、分离、髓芯减压后，骨髓干细胞和松质骨混合植入；对照组行髓芯减压松质骨植入。结果所有患者均获18个月的随访，行Harris评分和影像学检查。（1）髋关节Harris评分：治疗组由（55．90±9．71）分升至（81．86±7．95）分，优良率为87．5％；而对照组由（56．69±8．32）分升至（68．14±8．65）分，优良率为60．0％，两组比较差异有统计学意义（P〈0．01）；（2）髋关节影像学检查：治疗组仅1例（1髋）发展为Ⅲ期塌陷，而对照组2例（2髋）发展为Ⅲ期塌陷；MRI测得坏死面积百分比，治疗组由31．88％±7．59％降至13.20％±9．56％，而对照组由32．64％±6．32％降至21．18％±8．83％，两组比较差异有统计学意义（P〈0．05），结论髓芯减压植骨联合自体骨髓干细胞移值治疗早期股骨头坏死是一种安全、有效的方法，但还需要大样本临床试验及长期随访以进一步验证。展开更多
基金supported by grants from National Nature Science Foundation of China(No.30000083)Science and Technology Bureau of Shanghai Municipal Govemment(No.00JC 14042).
文摘Transforming growth factor-b 1 (TGF-β1), a multi-function polypeptide, is a double-edged sword in cancer. For some tumor cells, TGF-β1 is a potent growth inhibitor and apoptosis inducer. More commonly, TGF-β1 loses its growth-inhibitory and apoptosis-inducing effects, but stimulates the metastatic capacity of tumor cells. It is currently little known about TGF-β1-promoted cell migration in hepatocellular carcinoma (HCC) cells, let alone its mechanism. In this study, we found that TGF-β1 lost its tumor-suppressive effects, but significantly stimulated cell migration in SMMC-7721 human HCC cells. By FACS and Western blot analysis, we observed that TGF-β1 enhanced the expression of α5β1 integrin obviously, and subsequently stimulated cell adhesion onto fibronectin (Fn). Furthermore, we observed that TGF-β1 could also promote SMMC-7721 cells adhesion onto laminin (Ln). Our data also provided evidences that TGF-β1 induced epithelial-to-mesenchymal transformation (EMT) in SMMC-7721 cells. First, SMMC-7721 cells clearly switched to the spindle shape morphology after TGF-β1 treatment. Furthermore, TGF-β1 induced the down-regulation of E-cadherin and the nuclear translocation of β-catenin. These results indicated that TGF-β1-promoted cell adhesion and TGF-β1-induced epithelial-to-mesenchymal transformation might be both responsible for TGF-β1-enhanced cell migration.
文摘目的观察髓芯减压值骨联合自体骨髓干细胞移植治疗早期股骨头坏死的临床疗效。方法根据国际骨循环研究学会（Association Research Circulation Osseous，ARCO）骨坏死分期标准，选取Ⅰ、Ⅱ期股骨头坏死32例（39髋），治疗组18例（24髋），对照组14例（15髋）治疗组经过自体骨髓干细胞采集、分离、髓芯减压后，骨髓干细胞和松质骨混合植入；对照组行髓芯减压松质骨植入。结果所有患者均获18个月的随访，行Harris评分和影像学检查。（1）髋关节Harris评分：治疗组由（55．90±9．71）分升至（81．86±7．95）分，优良率为87．5％；而对照组由（56．69±8．32）分升至（68．14±8．65）分，优良率为60．0％，两组比较差异有统计学意义（P〈0．01）；（2）髋关节影像学检查：治疗组仅1例（1髋）发展为Ⅲ期塌陷，而对照组2例（2髋）发展为Ⅲ期塌陷；MRI测得坏死面积百分比，治疗组由31．88％±7．59％降至13.20％±9．56％，而对照组由32．64％±6．32％降至21．18％±8．83％，两组比较差异有统计学意义（P〈0．05），结论髓芯减压植骨联合自体骨髓干细胞移值治疗早期股骨头坏死是一种安全、有效的方法，但还需要大样本临床试验及长期随访以进一步验证。
